255 related articles for article (PubMed ID: 29987745)
1. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
2. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
[TBL] [Abstract][Full Text] [Related]
5. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
6. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
Rupoli S; Goteri G; Picardi P; Micucci G; Canafoglia L; Scortechini AR; Federici I; Giantomassi F; Da Lio L; Zizzi A; Honorati E; Leoni P
Diagn Pathol; 2015 Apr; 10():29. PubMed ID: 25885405
[TBL] [Abstract][Full Text] [Related]
8. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
9. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of prefibrotic myelofibrosis.
Rumi E; Sant'Antonio E; Boveri E; Pietra D; Cavalloni C; Roncoroni E; Astori C; Arcaini L;
Expert Rev Hematol; 2018 Jul; 11(7):537-545. PubMed ID: 29862872
[TBL] [Abstract][Full Text] [Related]
11. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
Jeryczynski G; Thiele J; Gisslinger B; Wölfler A; Schalling M; Gleiß A; Burgstaller S; Buxhofer-Ausch V; Sliwa T; Schlögl E; Geissler K; Krauth MT; Nader A; Vesely M; Simonitsch-Klupp I; Müllauer L; Beham-Schmid C; Gisslinger H
Am J Hematol; 2017 Sep; 92(9):885-891. PubMed ID: 28543356
[TBL] [Abstract][Full Text] [Related]
12. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
13. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
[TBL] [Abstract][Full Text] [Related]
14. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
[TBL] [Abstract][Full Text] [Related]
15. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
Mudireddy M; Barraco D; Hanson CA; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2017 May; 92(5):454-459. PubMed ID: 28211153
[TBL] [Abstract][Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Gangat N; Rambaldi A; Tefferi A; Barbui T
Leukemia; 2012 Apr; 26(4):716-9. PubMed ID: 21926959
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.
Gisslinger H; Jeryczynski G; Gisslinger B; Wölfler A; Burgstaller S; Buxhofer-Ausch V; Schalling M; Krauth MT; Schiefer AI; Kornauth C; Simonitsch-Klupp I; Beham-Schmid C; Müllauer L; Thiele J
Leukemia; 2016 May; 30(5):1126-32. PubMed ID: 26710883
[TBL] [Abstract][Full Text] [Related]
19. WHO classification of myeloproliferative neoplasms (MPN): A critical update.
Kvasnicka HM
Curr Hematol Malig Rep; 2013 Dec; 8(4):333-41. PubMed ID: 24146204
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
